Journal of Alzheimer's Disease最新文献_第3页

The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline. 脑脊液神经丝轻链与海马萎缩伴认知能力下降的关系。

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-10 DOI: 10.1177/13872877251365219

Ramkrishna K Singh, Semere Bekena, Nikitha Damera, Yiqi Zhu, Jean-Francois Trani, Ganesh M Babulal

{"title":"The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline.","authors":"Ramkrishna K Singh, Semere Bekena, Nikitha Damera, Yiqi Zhu, Jean-Francois Trani, Ganesh M Babulal","doi":"10.1177/13872877251365219","DOIUrl":"10.1177/13872877251365219","url":null,"abstract":"BackgroundIdentifying predictive biomarkers of cognitive decline is critical for timely intervention in early Alzheimer's disease and related dementia. Biomarkers such as cerebrospinal fluid (CSF) neurofilament light (NfL), and MRI-based hippocampal atrophy are potential indicators of neurodegeneration, but their long-term predictive value remains unclear.ObjectiveThis study examined 20-year longitudinal associations between CSF NfL, MRI-based hippocampal atrophy, and cognitive decline in cognitively normal older adults.MethodsA cohort of 279 cognitively normal adults aged ≥55 years was followed from 2003 to 2023 at the Knight ADRC. Participants underwent annual cognitive and neurological assessments, including Clinical Dementia Rating (CDR), CSF NfL quantification, and MRI-based hippocampal volumetry. Cognitive decline was defined as: (1) first progression (CDR ≥ 0.5) and (2) sustained progression (two consecutive CDRs ≥ 0.5). Analyses included Kaplan-Meier survival, Cox proportional hazards models, and linear mixed-effects (LME) models.ResultsParticipants had a mean age of 66.5 years (SD = 6.08); 58.4% were female. Mean follow-up was 11.41 years (SD = 3.5). First progression occurred in 71 participants (25.4%), and sustained progression in 35 (13%). Higher CSF NfL levels were associated with faster time to first (95% CI:0.2-1; p < 0.001) and sustained progression (95% CI:0.46-1; p = 0.008). Cox models showed increased risk of first progression (HR = 1.83; 95% CI: 1.11-3.01; p = 0.018) but not sustained (p = 0.093). LME models showed CSF NfL increase and hippocampal volume decline (p < 0.001) in both outcomes.ConclusionsCSF NfL is a strong predictor of cognitive decline and may serve as a screening biomarker for early dementia risk.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1143-1153"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interaction between gut microbiota and Alzheimer's disease: Re-analysis of the same sample. 肠道微生物群与阿尔茨海默病之间的相互作用：对同一样本的重新分析。

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-09-04 DOI: 10.1177/13872877251367359

Lu Wang, Xuhan Zuo, Mengyan Xu, Qiongwen Hu, Wenjuan Liang, Jinsheng Lu, Rongguang Zhang

{"title":"Interaction between gut microbiota and Alzheimer's disease: Re-analysis of the same sample.","authors":"Lu Wang, Xuhan Zuo, Mengyan Xu, Qiongwen Hu, Wenjuan Liang, Jinsheng Lu, Rongguang Zhang","doi":"10.1177/13872877251367359","DOIUrl":"10.1177/13872877251367359","url":null,"abstract":"BackgroundAlzheimer's disease (AD) is a neurodegenerative disease causing memory and cognitive dysfunction, and it is well established that the gut microbiota has an important effect on AD.ObjectiveIn this study, we aimed to identify evidence in AD affecting the abundance of gut microbiota, analyzing age and post-disease, with the expectation of discovering new gut microbiota combinations for diagnostic purposes.MethodsWe initially retrieved 219 samples from five studies in the GMrepo, and after screening, 86 samples collected from the same location were retained, with 98 species of gut microbiota at the genus level.ResultsIt was found that Clostridium, Ruminococcus, Roseburia, and Faecalibacterium were enriched in AD. We confirmed that AD altered the evenness of gut microbiota and validated the AD-induced significant changes in gut microbiota. For the impact of age on disease, we identified the most sensitive age group for AD detection by gut microbiota and the relevant species. When analyzing the association between AD and sex, we found that sex had no effect on the overall bacterial distribution, but in the subgroup analysis by sex, we identified significantly relevant species that could serve as diagnostic targets.ConclusionsThis study investigated the interaction between gut microbiota and AD utilizing an online free database and revealed a series of significant associations between the two. In the future, further emphasis should be placed on the identification of key bacteria and their associated genes to determine the relative causality of gut microbiota and AD.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1240-1255"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the stability of Alzheimer's disease plasma biomarkers stored for extended periods at -20°C: Implications for resource-constrained environments. 探索阿尔茨海默病血浆生物标志物在-20°C下长时间储存的稳定性：对资源受限环境的影响

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-03 DOI: 10.1177/13872877251364899

Biniyam A Ayele, Patrice L Whitehead, Julianna Pascual, Tianjie Gu, Farid Rajabli, Jamie Arvizu, Charles G Golightly, Larry D Adams, Margaret A Pericak-Vance, Jeffery M Vance, Anthony J Griswold

引用次数: 0

Correlations of retinal morphology with clinical symptoms, blood-brain barrier, and brain structure in patients with Alzheimer's disease. 阿尔茨海默病患者视网膜形态与临床症状、血脑屏障和脑结构的相关性

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-08 DOI: 10.1177/13872877251364736

Jing Qi, Mingyue He, Tenghong Lian, Shuran Wang, Peng Guo, Jinghui Li, Jing Li, Dongmei Luo, Yanan Zhang, Yue Huang, Gaifen Liu, Huiying Guan, Weijia Zhang, Hao Yue, Zijing Zheng, Fan Zhang, Zhan Liu, Ruidan Wang, Wenjing Zhang, Yao Meng, Wei Zhang

{"title":"Correlations of retinal morphology with clinical symptoms, blood-brain barrier, and brain structure in patients with Alzheimer's disease.","authors":"Jing Qi, Mingyue He, Tenghong Lian, Shuran Wang, Peng Guo, Jinghui Li, Jing Li, Dongmei Luo, Yanan Zhang, Yue Huang, Gaifen Liu, Huiying Guan, Weijia Zhang, Hao Yue, Zijing Zheng, Fan Zhang, Zhan Liu, Ruidan Wang, Wenjing Zhang, Yao Meng, Wei Zhang","doi":"10.1177/13872877251364736","DOIUrl":"10.1177/13872877251364736","url":null,"abstract":"BackgroundPatients with Alzheimer's disease (AD) displayed abnormal retinal morphology; however, its potential associations with clinical symptoms, damage of the blood-brain barrier (BBB), and brain structure are unclear.ObjectiveTo investigate the correlations of retinal morphology with clinical symptoms, BBB damage, and brain structure in AD patients.MethodsIn 97 patients with mild cognitive impairment due to AD (AD-MCI) and dementia due to AD (AD-D), retinal morphology, clinical symptoms, BBB variables in cerebrospinal fluid, and brain structure variables, including medial temporal atrophy (MTA), global cortical atrophy (GCA), and white matter hyperintensities scores were evaluated.ResultsIn AD patients, peripapillary superotemporal retinal nerve fiber layer thickness (NFLT) was positively correlated with memory score; the NFLTs of average, inferior, and inferotemporal quadrants were negatively correlated with the level of matrix metalloproteinase 3 level in cerebrospinal fluid; the NFLTs of average, superior, and inferior quadrants were negatively correlated with MTA and GCA scores; superotemporal NFLT was negatively correlated with GCA score. In AD-MCI group, superotemporal NFLT maintained a positive correlation with memory score; the NFLTs in superior and nasoupper quadrants were negatively associated with GCA score. In AD-D group, superonasal NFLT was negatively correlated with matrix metalloproteinase 9 level in cerebrospinal fluid.ConclusionsIn AD patients, thinner peripapillary NFLT mirrors worse memory, significant BBB damage, the atrophy of medial temporal lobe and cortex. In AD-MCI patients, thinner NFLT mirrors worse memory and cortical atrophy. In AD-D patients, thinner NFLT mirrors significant BBB damage.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1013-1025"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global burden trends of Alzheimer's disease and other dementias attributable to smoking from 1990 to 2021. 1990年至2021年由吸烟引起的阿尔茨海默病和其他痴呆症的全球负担趋势。

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1177/13872877251365284

Yanming Lv, Yi Xiang, Wenhao Fu, Baixiang Li, Xueting Li

{"title":"Global burden trends of Alzheimer's disease and other dementias attributable to smoking from 1990 to 2021.","authors":"Yanming Lv, Yi Xiang, Wenhao Fu, Baixiang Li, Xueting Li","doi":"10.1177/13872877251365284","DOIUrl":"10.1177/13872877251365284","url":null,"abstract":"BackgroundSmoking is a major modifiable risk factor for Alzheimer's disease and other dementias (ADODs), but comprehensive assessments of its global burden remain scarce.ObjectiveThis study examines spatiotemporal trends in smoking-attributable ADODs across 204 countries and territories from 1990 to 2021.MethodsUsing data from the Global Burden of Disease (GBD) 2021 study, we estimated smoking-attributable mortality, disability-adjusted life years (DALYs), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR). Temporal trends were quantified via estimated annual percentage change (EAPC), and future trajectories were projected using autoregressive integrated moving average (ARIMA) models.ResultsBetween 1990 and 2021, global smoking-attributable ADOD deaths and DALYs increased by 108.85% (67,176 deaths) and 92.88% (1.53 million DALYs), respectively. However, age-standardized rates declined significantly: ASMR decreased by 22.22% (EAPC = -0.95, 95% CI: -0.99, -0.91) and ASDR by 21.30% (EAPC = -0.88, 95% CI: -0.92, -0.83). Men exhibited higher baseline rates, but women experienced steeper declines (ASMR EAPC: -1.60vs-0.79). Elderly populations disproportionately bore the highest burden, especially those ≥65 years. The middle-SDI region bore the heaviest burden (47,038,000 DALYs), while East Asia accounted for 38% of deaths. Projections suggest that the burden of smoking-related ADOD may continue to rise by 2036.ConclusionsThe burden of smoking-related ADODs remains high, with marked disparities across age, gender and socioeconomic strata. Targeted interventions, such as tobacco taxation, smoking bans, and integrated cognitive screening programs.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1154-1167"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-omics profiling reveals two distinct trajectories in the progression from mild cognitive impairment to Alzheimer's disease. 多组学分析揭示了从轻度认知障碍到阿尔茨海默病的两个不同的发展轨迹。

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1177/13872877251365210

Xiayao Guo, Hongwen Fu, Ming Qin, Jiahui Kan

{"title":"Multi-omics profiling reveals two distinct trajectories in the progression from mild cognitive impairment to Alzheimer's disease.","authors":"Xiayao Guo, Hongwen Fu, Ming Qin, Jiahui Kan","doi":"10.1177/13872877251365210","DOIUrl":"10.1177/13872877251365210","url":null,"abstract":"BackgroundAlzheimer's disease (AD) exhibits significant clinical and pathological heterogeneity, particularly during the mild cognitive impairment (MCI) transitional stage. Current understanding of the molecular drivers underlying distinct MCI progression trajectories remains incomplete, hindering the development of personalized interventions.ObjectiveThis study aims to integrate transcriptomic, epigenomic, and metabolomic data to identify distinct trajectories in the progression from MCI to AD, and to explore the underlying disease heterogeneity.MethodsWe integrated transcriptomic, epigenomic, and metabolomic data from MCI patients to model the progression to AD and stratified them into subtypes. We then examined molecular differences between MCI and AD within each subtype, identifying key immune microenvironments and regulatory pathways via immune cell infiltration analysis, WGCNA, and GO/KEGG analyses. Finally, we applied Cox regression to identify prognostic biomarkers and built a random forest prognostic model.ResultsOur analysis identified two distinct MCI-to-AD progression subtypes. Subtype 1 was marked by metabolic dysregulation and slower cognitive decline, while Subtype 2 was driven by chronic immune activation and exhibited faster cognitive decline. The trajectory subtypes captured molecular perturbations that were missed by traditional unclustered methods. Prognostic models based on these molecular signatures predicted disease progression over 1-5 years, with AUROC values ranging from 0.851 to 0.893 for Subtype 1 and from 0.878 to 0.927 for Subtype 2.ConclusionsOur findings highlight the importance of multi-omics trajectory stratification in understanding the heterogeneity of AD progression. The identification of two distinct progression trajectories provides insights into the underlying mechanisms of AD.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1080-1096"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of mitochondrial dysfunction in diabetes-associated cognitive dysfunction: A bibliometric analysis. 线粒体功能障碍在糖尿病相关认知功能障碍中的作用：文献计量学分析。

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-06 DOI: 10.1177/13872877251364845

Chen Wang, Siyi He, Lingling Wang, Yushuang Yin, Wenqi Zhang, Guanwen Lin, Duozhi Wu, Qin Zhou, Zhihua Wang

{"title":"The role of mitochondrial dysfunction in diabetes-associated cognitive dysfunction: A bibliometric analysis.","authors":"Chen Wang, Siyi He, Lingling Wang, Yushuang Yin, Wenqi Zhang, Guanwen Lin, Duozhi Wu, Qin Zhou, Zhihua Wang","doi":"10.1177/13872877251364845","DOIUrl":"10.1177/13872877251364845","url":null,"abstract":"BackgroundDiabetes, a prevalent chronic disorder, is frequently complicated by diabetes-associated cognitive dysfunction (DACD). The impact of diabetes on specific cerebral regions accelerates the progression from mild cognitive impairment to Alzheimer's disease. Research has indicated that mitochondrial dysfunction is a pivotal factor in DACD, yet its underlying mechanisms remain elusive.ObjectiveOur research aims to elucidate the research trends in this field over the past fifteen years by employing bibliometric analysis.MethodsA systematic search and aggregation of literatures related to mitochondrial dysfunction in DACD published within the Web of Science Core Collection from 2010 to 2024 were performed. Subsequently, a bibliometric analysis was conducted employing four bibliometric software: HistCite, R-bibliometrix, VOSviewer, and CiteSpace.ResultsA total of 309 papers were identified for analysis. The most prolific country, institution, and authors were China, University of Coimbra, Moreira PI, and Li YS, respectively. The USA, Texas Tech University, and Reddy PH were the key country, institution, and author, respectively. Among references to articles in this field, Diabetes has the most cumulative citations. According to the analysis of co-citations, oxidative stress was the largest cluster. The primary keywords were \"Alzheimer's disease\" and \"oxidative stress\". In recent years, the keyword \"mitophagy\" has received a lot of attention.ConclusionsOxidative stress represents a principal research topic within this field. Mitophagy offers a potential therapeutic avenue for DACD and may emerge as a novel focus of future investigations.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1038-1053"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commonalities in cortical neurodegeneration between type 2 diabetes and Alzheimer's disease. 2型糖尿病和阿尔茨海默病皮质神经变性的共性

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-10 DOI: 10.1177/13872877251365671

Mahboubeh Motaghi, Olivier Potvin, Simon Duchesne

{"title":"Commonalities in cortical neurodegeneration between type 2 diabetes and Alzheimer's disease.","authors":"Mahboubeh Motaghi, Olivier Potvin, Simon Duchesne","doi":"10.1177/13872877251365671","DOIUrl":"10.1177/13872877251365671","url":null,"abstract":"BackgroundType 2 diabetes (T2D) is a prevalent metabolic condition associated with increased risk of cognitive decline and dementia, including Alzheimer's disease (AD). While both T2D and AD are linked to neurodegeneration, the extent to which their patterns of brain atrophy overlap remain unclear.ObjectiveTo assess the similarities and differences in cortical atrophy patterns among individuals with controlled and uncontrolled T2D, mild cognitive impairment (MCI), and AD.MethodsStructural magnetic resonance imaging data from the UK Biobank (UKBB) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) were analyzed. Participants aged 55 and older were selected. Linear regression models were applied to generate cortical thickness maps for each group, controlling for age and sex. Group comparisons were conducted using permutation-based tests accounting for spatial autocorrelation.ResultsThe study included 175 individuals with T2D (86 uncontrolled, 89 controlled) and 127 healthy controls without diabetes (HC) from UKBB, 334 individuals with MCI, 119 with AD and 315 cognitively healthy (CH) from ADNI. Uncontrolled T2D was associated with significant cortical atrophy in specific brain regions, with partial overlap in neurodegeneration patterns observed in MCI and AD. However, correlations between the cortical thinning patterns were weak and non-significant, suggesting distinct trajectories. Controlled T2D showed no significant cortical thinning, supporting the potential neuroprotective effects of glycemic control.ConclusionsUncontrolled T2D is linked to region-specific cortical atrophy that partially overlaps with MCI and AD but follows an independent neurodegenerative trajectory. Effective diabetes management may help preserve brain structure and reduce dementia risk, highlighting the importance of early metabolic intervention.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1304-1318"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of cerebellar intermittent theta-burst stimulation on patients with Alzheimer's disease: A randomized controlled trial. 小脑间歇性脉冲刺激对阿尔茨海默病患者的影响：一项随机对照试验。

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-13 DOI: 10.1177/13872877251366656

Xin Zhang, Zhongqing Sun, Dianwei Wu, Xiaojing Shi, Changgeng Song, Xiao Guan, Jianmin Hao, Yaomin Guo, Xiaorui Wang, Dong Wei, Zhirong Liu, Jingjing Zhao, Wen Jiang

{"title":"Effects of cerebellar intermittent theta-burst stimulation on patients with Alzheimer's disease: A randomized controlled trial.","authors":"Xin Zhang, Zhongqing Sun, Dianwei Wu, Xiaojing Shi, Changgeng Song, Xiao Guan, Jianmin Hao, Yaomin Guo, Xiaorui Wang, Dong Wei, Zhirong Liu, Jingjing Zhao, Wen Jiang","doi":"10.1177/13872877251366656","DOIUrl":"10.1177/13872877251366656","url":null,"abstract":"BackgroundThe cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention in Alzheimer's disease (AD).ObjectiveThis study aimed to investigate the effect of cerebellar intermittent theta-burst stimulation (iTBS) in patients with AD.MethodsWe conducted a randomized, double-blind, sham-controlled clinical trial in which patients were randomly allocated to receive either active-iTBS or sham-iTBS. The primary outcome was the change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scores from baseline to week 4. Secondary outcomes included evaluations of neurophysiological measures, brain network functions, and glymphatic clearance.ResultsFrom April 20 to June 25, 2024, 20 patients were analyzed. Compared with sham-iTBS, active-iTBS significantly improved cognition at week 4, indicated by reduced CDR-SB scores (mean changes: -0.60 versus 0.15; adjusted β: 0.73; 95% CI, 0.17-1.26). In the active-iTBS group compared with the sham-iTBS group, the power spectral density in electroencephalogram revealed global decreased in theta power (adjusted β, -0.014; 95% CI, -0.024-0.003) and increased beta power (adjusted β, 0.002; 95%CI, 0.000-0.005), the functional magnetic resonance imaging demonstrated enhanced the gradient values of default mode network activity along the principal gradient, and the structural magnetic resonance imaging indicated an improvement in glymphatic clearance (adjusted β, 0.097, 95% CI, 0.0381-0.1603).ConclusionsA four-week course of iTBS improved cognitive function in patients with AD, possibly via promoting the Beta frequency band power, enhancing brain network functionality, and facilitating glymphatic clearance.Trial registrationClinicalTrials.gov (NCT06379100, April 14, 2024).","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1187-1199"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis. 降糖治疗对2型糖尿病合并阿尔茨海默病患者认知功能影响的综合分析

IF 3.1 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-10-01 Epub Date: 2025-08-25 DOI: 10.1177/13872877251365662

Chen Jiang, Junnan Qi, Hongyi Zou, Oscar Lopez, Xiang-Qun Xie, Ying Xue

{"title":"Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis.","authors":"Chen Jiang, Junnan Qi, Hongyi Zou, Oscar Lopez, Xiang-Qun Xie, Ying Xue","doi":"10.1177/13872877251365662","DOIUrl":"10.1177/13872877251365662","url":null,"abstract":"BackgroundSeveral hypotheses suggest that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD), and antidiabetic medications may influence cognitive function in these patients.ObjectiveThis study aims to provide a comprehensive evaluation of the impact of single and combination antidiabetic therapies on cognitive function in patients with both AD and T2DM.MethodsWe analyzed data from the National Alzheimer's Coordinating Center (NACC), covering a 17-year period from June 2005 to August 2022. This study included 3234 patients with both AD and T2DM. After applying exclusion criteria, 964 patients were analyzed using propensity score matching and a generalized linear mixed model. Patients were categorized based on their longitudinal use of oral antidiabetic medications.ResultsBased on the 964 patients' cohort, the study found that patients receiving metformin with sulfonylureas (RR = 1.105 [1.022, 1.195], p = 0.013) and metformin with a dipeptidyl peptidase 4 inhibitor (DPP-4i) (RR = 1.132 [1.021, 1.256], p = 0.019) experienced a significantly slower decline in MMSE scores over time when compared to patients receiving metformin with thiazolidinediones (TZD).ConclusionsThis study demonstrates that combination therapies involving metformin with sulfonylureas or DPP-4i are associated with a slower rate of cognitive decline compared to metformin with TZD in patients with AD and T2DM. These findings provide novel evidence for the long-term cognitive benefits of specific antidiabetic therapies and offer valuable insights for clinical decision-making in this dual-affected population.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"1294-1303"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0